{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:44:55Z","timestamp":1792788295644,"version":"4.5.0"},"reference-count":173,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20251842"],"award-info":[{"award-number":["BK20251842"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Northern Jiangsu Clinical Medicine Research Institute's 2024 Projects","award":["HAKY202400313"],"award-info":[{"award-number":["HAKY202400313"]}]},{"name":"The Development Fund of Affiliated Hospital of Xuzhou Medical University","award":["XYFC202302"],"award-info":[{"award-number":["XYFC202302"]}],"id":[{"id":"https:\/\/ror.org\/02kstas42","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alzheimer\u2019s disease (AD) is a significant global health challenge characterized as a multifactorial neurodegenerative disorder, involving amyloid-\u03b2 (A\u03b2) and Tau aggregation, neuroinflammation and progressive neuronal injury. While Amyloid-targeted therapies have achieved a breakthrough in prevention of A\u03b2 aggregation, the strategies face notable limitations in achieving curative outcomes and management of amyloid-independent central nervous system (CNS) dysfunction. Consequently, targeting microglia, the central immune cells of the brain, has emerged as a promising strategy to enhance the specificity and efficacy of AD interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main body<\/jats:title>\n                    <jats:p>Accumulating evidence indicates microglial dysfunction is not a passive immune bystander of AD, but serves as a critical mechanistic nexus linking A\u03b2 accumulation and AD symptomatic phenotype. This review critically examines the \u201cnext generation\u201d of microglial therapeutics, moving beyond broad immunosuppression to precision phenotype modulation. We highlight breakthrough strategies in recent years including immune reconstitution, metabolic reprogramming, nanomaterial-mediated drug delivery, and the revolutionary potential of iPSC-derived microglia replacement. By elucidating the rationale underlying the specific strategies based on microglial biofunction and potential molecular mechanism in AD pathology, we provide an overview of current development of clinical trials and cutting-edge modalities aimed at restoring microglial homeostasis, affording an opportunity to alter the AD trajectory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This review aims to delineate the path from bench to bedside and propose promising pathways to overcome current bottlenecks in AD drug development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40659-026-00716-8","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T09:24:34Z","timestamp":1783675474000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reshaping the immune landscape: next-generation microglia-targeted therapies for Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"59","author":[{"given":"Jun","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jueying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7618-0670","authenticated-orcid":false,"given":"Fangyi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"716_CR1","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S1474-4422(17)30077-7","volume":"16","author":"CR Jack Jr.","year":"2017","unstructured":"Jack CR Jr., et al. Age-specific and sex-specific prevalence of cerebral \u03b2-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study. Lancet Neurol. 2017;16:435\u201344.","journal-title":"Lancet Neurol"},{"key":"716_CR2","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","volume":"179","author":"JM Long","year":"2019","unstructured":"Long JM, Holtzman DM. Alzheimer disease: An update on pathobiology and treatment strategies. Cell. 2019;179:312\u201339.","journal-title":"Cell"},{"key":"716_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102203","volume":"94","author":"I Terao","year":"2024","unstructured":"Terao I, Kodama W. Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer\u2019s disease: a systematic review and network meta-analysis. Ageing Res Rev. 2024;94:102203.","journal-title":"Ageing Res Rev"},{"key":"716_CR4","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/S0140-6736(25)01389-3","volume":"406","author":"GB Frisoni","year":"2025","unstructured":"Frisoni GB, et al. Alzheimer\u2019s disease outlook: controversies and future directions. Lancet. 2025;406:1424\u201342.","journal-title":"Lancet"},{"key":"716_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13073-023-01155-w","volume":"15","author":"M Jorfi","year":"2023","unstructured":"Jorfi M, Maaser-Hecker A, Tanzi RE. The neuroimmune axis of Alzheimer\u2019s disease. Genome Med. 2023;15:6.","journal-title":"Genome Med"},{"key":"716_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-025-00812-5","volume":"20","author":"S Zhang","year":"2025","unstructured":"Zhang S, et al. Peripheral and central neuroimmune mechanisms in Alzheimer\u2019s disease pathogenesis. Mol Neurodegener. 2025;20:22.","journal-title":"Mol Neurodegener"},{"key":"716_CR7","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1038\/s41467-023-37437-5","volume":"14","author":"L Brase","year":"2023","unstructured":"Brase L, et al. Single-nucleus RNA-sequencing of autosomal dominant Alzheimer disease and risk variant carriers. Nat Commun. 2023;14:2314.","journal-title":"Nat Commun"},{"key":"716_CR8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41586-025-09662-z","volume":"648","author":"P Ayata","year":"2025","unstructured":"Ayata P, et al. Lymphoid gene expression supports neuroprotective microglia function. Nature. 2025;648:157\u201365.","journal-title":"Nature"},{"key":"716_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388:9\u201321.","journal-title":"N Engl J Med"},{"key":"716_CR10","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, et al. Donanemab in early Alzheimer\u2019s disease. N Engl J Med. 2021;384:1691\u2013704.","journal-title":"N Engl J Med"},{"key":"716_CR11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41577-024-01104-7","volume":"25","author":"MT Heneka","year":"2025","unstructured":"Heneka MT, et al. Neuroinflammation in Alzheimer disease. Nat Rev Immunol. 2025;25:321\u201352.","journal-title":"Nat Rev Immunol"},{"key":"716_CR12","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.1016\/j.cell.2022.09.033","volume":"185","author":"S Wang","year":"2022","unstructured":"Wang S, et al. TREM2 drives microglia response to amyloid-\u03b2 via SYK-dependent and -independent pathways. Cell. 2022;185:4153-4169.e4119.","journal-title":"Cell"},{"key":"716_CR13","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1038\/s41380-024-02474-z","volume":"29","author":"E Wong","year":"2024","unstructured":"Wong E, et al. HuM195 and its single-chain variable fragment increase A\u03b2 phagocytosis in microglia via elimination of CD33 inhibitory signaling. Mol Psychiatry. 2024;29:2084\u201394.","journal-title":"Mol Psychiatry"},{"key":"716_CR14","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.immuni.2017.08.008","volume":"47","author":"S Krasemann","year":"2017","unstructured":"Krasemann S, et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 2017;47:566-581.e569.","journal-title":"Immunity"},{"key":"716_CR15","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1016\/j.immuni.2023.08.008","volume":"56","author":"AP Tsai","year":"2023","unstructured":"Tsai AP, et al. Genetic variants of phospholipase C-\u03b32 alter the phenotype and function of microglia and confer differential risk for Alzheimer\u2019s disease. Immunity. 2023;56:2121-2136.e2126.","journal-title":"Immunity"},{"key":"716_CR16","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.immuni.2022.07.004","volume":"55","author":"A Silvin","year":"2022","unstructured":"Silvin A, et al. Dual ontogeny of disease-associated microglia and disease inflammatory macrophages in aging and neurodegeneration. Immunity. 2022;55:1448-1465.e1446.","journal-title":"Immunity"},{"key":"716_CR17","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20212479","author":"N Zhao","year":"2022","unstructured":"Zhao N, et al. Elevating microglia TREM2 reduces amyloid seeding and suppresses disease-associated microglia. J Exp Med. 2022. https:\/\/doi.org\/10.1084\/jem.20212479.","journal-title":"J Exp Med"},{"key":"716_CR18","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/s41590-023-01627-6","volume":"24","author":"Z Yin","year":"2023","unstructured":"Yin Z, et al. APOE4 impairs the microglial response in Alzheimer\u2019s disease by inducing TGF\u03b2-mediated checkpoints. Nat Immunol. 2023;24:1839\u201353.","journal-title":"Nat Immunol"},{"key":"716_CR19","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/s41593-018-0242-x","volume":"21","author":"S Hickman","year":"2018","unstructured":"Hickman S, Izzy S, Sen P, Morsett L, El Khoury J. Microglia in neurodegeneration. Nat Neurosci. 2018;21:1359\u201369.","journal-title":"Nat Neurosci"},{"key":"716_CR20","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.cell.2018.05.003","volume":"173","author":"A Deczkowska","year":"2018","unstructured":"Deczkowska A, et al. Disease-associated microglia: a universal immune sensor of neurodegeneration. Cell. 2018;173:1073\u201381.","journal-title":"Cell"},{"key":"716_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40168-022-01232-z","volume":"10","author":"LM Cox","year":"2022","unstructured":"Cox LM, et al. The microbiota restrains neurodegenerative microglia in a model of amyotrophic lateral sclerosis. Microbiome. 2022;10:47.","journal-title":"Microbiome"},{"key":"716_CR22","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1016\/j.neuron.2022.06.023","volume":"110","author":"VW Yong","year":"2022","unstructured":"Yong VW. Microglia in multiple sclerosis: protectors turn destroyers. Neuron. 2022;110:3534\u201348.","journal-title":"Neuron"},{"key":"716_CR23","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature21029","volume":"541","author":"SA Liddelow","year":"2017","unstructured":"Liddelow SA, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481\u20137.","journal-title":"Nature"},{"key":"716_CR24","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/S1474-4422(19)30435-1","volume":"19","author":"SJ Andrews","year":"2020","unstructured":"Andrews SJ, Fulton-Howard B, Goate A. Interpretation of risk loci from genome-wide association studies of Alzheimer\u2019s disease. Lancet Neurol. 2020;19:326\u201335.","journal-title":"Lancet Neurol"},{"key":"716_CR25","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.neuron.2013.02.026","volume":"78","author":"C Cruchaga","year":"2013","unstructured":"Cruchaga C, et al. GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer\u2019s disease. Neuron. 2013;78:256\u201368.","journal-title":"Neuron"},{"key":"716_CR26","doi-asserted-by":"crossref","unstructured":"Kober DL, et al. Functional insights from biophysical study of TREM2 interactions with apoE and A\u03b2 (1\u201342). Alzheimers Dement. (2020).","DOI":"10.1101\/2020.02.24.963264"},{"key":"716_CR27","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201809027","author":"CB Lessard","year":"2018","unstructured":"Lessard CB, et al. High-affinity interactions and signal transduction between A\u03b2 oligomers and TREM2. EMBO Mol Med. 2018. https:\/\/doi.org\/10.15252\/emmm.201809027.","journal-title":"EMBO Mol Med"},{"key":"716_CR28","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.neuron.2018.01.031","volume":"97","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, et al. TREM2 is a receptor for \u03b2-amyloid that mediates microglial function. Neuron. 2018;97:1023-1031.e1027.","journal-title":"Neuron"},{"key":"716_CR29","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1084\/jem.20151948","volume":"213","author":"Y Wang","year":"2016","unstructured":"Wang Y, et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med. 2016;213:667\u201375.","journal-title":"J Exp Med"},{"key":"716_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100631","volume":"296","author":"A Vilalta","year":"2021","unstructured":"Vilalta A, et al. Wild-type sTREM2 blocks A\u03b2 aggregation and neurotoxicity, but the Alzheimer\u2019s R47H mutant increases A\u03b2 aggregation. J Biol Chem. 2021;296:100631.","journal-title":"J Biol Chem"},{"key":"716_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3009093","volume":"6","author":"G Kleinberger","year":"2014","unstructured":"Kleinberger G, et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med. 2014;6:243\u2013286.","journal-title":"Sci Transl Med"},{"key":"716_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcad286","volume":"5","author":"F Nabizadeh","year":"2023","unstructured":"Nabizadeh F. sTREM2 is associated with attenuated tau aggregate accumulation in the presence of amyloid-\u03b2 pathology. Brain Commun. 2023;5:fcad286.","journal-title":"Brain Commun"},{"key":"716_CR33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13024-020-00407-2","volume":"15","author":"N Franzmeier","year":"2020","unstructured":"Franzmeier N, et al. Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration. Mol Neurodegener. 2020;15:57.","journal-title":"Mol Neurodegener"},{"key":"716_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-020-00374-8","volume":"15","author":"LZ Ma","year":"2020","unstructured":"Ma LZ, et al. Dynamic changes of CSF sTREM2 in preclinical Alzheimer\u2019s disease: the CABLE study. Mol Neurodegener. 2020;15:25.","journal-title":"Mol Neurodegener"},{"key":"716_CR35","doi-asserted-by":"publisher","DOI":"10.1172\/JCI158708","author":"A Zhao","year":"2022","unstructured":"Zhao A, et al. Soluble TREM2 levels associate with conversion from mild cognitive impairment to Alzheimer\u2019s disease. J Clin Invest. 2022. https:\/\/doi.org\/10.1172\/JCI158708.","journal-title":"J Clin Invest"},{"key":"716_CR36","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/s41593-024-01620-8","volume":"27","author":"N Rachmian","year":"2024","unstructured":"Rachmian N, et al. Identification of senescent, TREM2-expressing microglia in aging and Alzheimer\u2019s disease model mouse brain. Nat Neurosci. 2024;27:1116\u201324.","journal-title":"Nat Neurosci"},{"key":"716_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19227-5","volume":"11","author":"A McQuade","year":"2020","unstructured":"McQuade A, et al. Gene expression and functional deficits underlie TREM2-knockout microglia responses in human models of Alzheimer\u2019s disease. Nat Commun. 2020;11:5370.","journal-title":"Nat Commun"},{"key":"716_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/alz.072079","volume":"19","author":"K Schlepckow","year":"2023","unstructured":"Schlepckow K. Therapeutic targeting of TREM2: a novel approach for treatment of AD? Alzheimers Dement. 2023;19:e072079.","journal-title":"Alzheimers Dement"},{"key":"716_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01599-1","volume":"16","author":"H Long","year":"2024","unstructured":"Long H, et al. Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer\u2019s disease. Alzheimers Res Ther. 2024;16:235.","journal-title":"Alzheimers Res Ther"},{"key":"716_CR40","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1038\/s41591-026-04273-1","volume":"32","author":"CJ Mummery","year":"2026","unstructured":"Mummery CJ, et al. The TREM2 agonistic antibody AL002 in early Alzheimer\u2019s disease: a phase 2 randomized trial. Nat Med. 2026;32:1708\u201316.","journal-title":"Nat Med"},{"key":"716_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/alz.084622","volume":"20","author":"C Mirescu","year":"2024","unstructured":"Mirescu C. Characterization of the first TREM2 small molecule agonist, VG-3927, for clinical development in Alzheimer\u2019s disease. Alzheimers Dement. 2024;20:e084622.","journal-title":"Alzheimers Dement"},{"key":"716_CR42","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s40035-025-00515-3","volume":"14","author":"X Qi","year":"2025","unstructured":"Qi X, et al. Roles of TREM2 in Alzheimer\u2019s disease. Transl Neurodegenerat. 2025;14:55.","journal-title":"Transl Neurodegenerat"},{"key":"716_CR43","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adu3761","volume":"18","author":"NK Malhi","year":"2026","unstructured":"Malhi NK, et al. Diabetes-induced TREM2-endothelial cell signaling impairs ischemic vascular repair. Sci Transl Med. 2026;18:eadu3761.","journal-title":"Sci Transl Med"},{"key":"716_CR44","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","volume":"169","author":"H Keren-Shaul","year":"2017","unstructured":"Keren-Shaul H, et al. A unique microglia type associated with restricting development of Alzheimer\u2019s disease. Cell. 2017;169:1276-1290.e1217.","journal-title":"Cell"},{"key":"716_CR45","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1093\/brain\/awaf200","volume":"149","author":"AM Abdel-Haleem","year":"2026","unstructured":"Abdel-Haleem AM, et al. CSF proteomics of semorinemab Alzheimer\u2019s disease trials identifies cell-type specific signatures. Brain. 2026;149:150\u201362.","journal-title":"Brain"},{"key":"716_CR46","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1002\/alz.13764","volume":"20","author":"MR Meyer","year":"2024","unstructured":"Meyer MR, et al. Clinical validation of the PrecivityAD2 blood test: a mass spectrometry-based test with algorithm combining %p-tau217 and A\u03b242\/40 ratio to identify presence of brain amyloid. Alzheimers Dement. 2024;20:3179\u201392.","journal-title":"Alzheimers Dement"},{"key":"716_CR47","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41467-019-13901-z","volume":"11","author":"K Kim","year":"2020","unstructured":"Kim K, et al. Clinically accurate diagnosis of Alzheimer\u2019s disease via multiplexed sensing of core biomarkers in human plasma. Nat Commun. 2020;11:119.","journal-title":"Nat Commun"},{"key":"716_CR48","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/s43587-026-01088-0","volume":"6","author":"ER Blujdea","year":"2026","unstructured":"Blujdea ER, et al. Microglia protein profiles in CSF across Alzheimer\u2019s disease clinical stages. Nat Aging. 2026;6:520\u201333.","journal-title":"Nat Aging"},{"key":"716_CR49","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.brainresbull.2020.01.003","volume":"156","author":"L Liu","year":"2020","unstructured":"Liu L, et al. Multiple inflammatory profiles of microglia and altered neuroimages in APP\/PS1 transgenic AD mice. Brain Res Bull. 2020;156:86\u2013104.","journal-title":"Brain Res Bull"},{"key":"716_CR50","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.immuni.2022.03.018","volume":"55","author":"ER Roy","year":"2022","unstructured":"Roy ER, et al. Concerted type I interferon signaling in microglia and neural cells promotes memory impairment associated with amyloid \u03b2 plaques. Immunity. 2022;55:879-894.e876.","journal-title":"Immunity"},{"key":"716_CR51","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nri3705","volume":"14","author":"MT Heneka","year":"2014","unstructured":"Heneka MT, Kummer MP, Latz E. Innate immune activation in neurodegenerative disease. Nat Rev Immunol. 2014;14:463\u201377.","journal-title":"Nat Rev Immunol"},{"key":"716_CR52","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41582-020-00435-y","volume":"17","author":"F Leng","year":"2021","unstructured":"Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: Where do we go from here? Nat Rev Neurol. 2021;17:157\u201372.","journal-title":"Nat Rev Neurol"},{"key":"716_CR53","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41586-019-1769-z","volume":"575","author":"C Ising","year":"2019","unstructured":"Ising C, et al. NLRP3 inflammasome activation drives tau pathology. Nature. 2019;575:669\u201373.","journal-title":"Nature"},{"key":"716_CR54","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/ni.1636","volume":"9","author":"A Halle","year":"2008","unstructured":"Halle A, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol. 2008;9:857\u201365.","journal-title":"Nat Immunol"},{"key":"716_CR55","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/cr.2013.24","volume":"23","author":"T Goldmann","year":"2013","unstructured":"Goldmann T, Tay TL, Prinz M. Love and death: microglia, NLRP3 and the Alzheimer\u2019s brain. Cell Res. 2013;23:595\u20136.","journal-title":"Cell Res"},{"key":"716_CR56","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13024-023-00674-9","volume":"18","author":"G Terzioglu","year":"2023","unstructured":"Terzioglu G, Young-Pearse TL. Microglial function, INPP5D\/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer\u2019s disease. Mol Neurodegener. 2023;18:89.","journal-title":"Mol Neurodegener"},{"key":"716_CR57","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.immuni.2024.03.010","volume":"57","author":"S Castro-Gomez","year":"2024","unstructured":"Castro-Gomez S, Heneka MT. Innate immune activation in neurodegenerative diseases. Immunity. 2024;57:790\u2013814.","journal-title":"Immunity"},{"key":"716_CR58","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nature11729","volume":"493","author":"MT Heneka","year":"2013","unstructured":"Heneka MT, et al. NLRP3 is activated in Alzheimer\u2019s disease and contributes to pathology in APP\/PS1 mice. Nature. 2013;493:674\u20138.","journal-title":"Nature"},{"key":"716_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.503","volume":"4","author":"B Parajuli","year":"2013","unstructured":"Parajuli B, et al. Oligomeric amyloid \u03b2 induces IL-1\u03b2 processing via production of ROS: implication in Alzheimer\u2019s disease. Cell Death Dis. 2013;4:e975.","journal-title":"Cell Death Dis"},{"key":"716_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2024.105868","volume":"165","author":"TQ Ge","year":"2024","unstructured":"Ge TQ, Guan PP, Wang P. Complement 3a induces the synapse loss via C3aR in mitochondria-dependent NLRP3 activating mechanisms during the development and progression of Alzheimer\u2019s disease. Neurosci Biobehav Rev. 2024;165:105868.","journal-title":"Neurosci Biobehav Rev"},{"key":"716_CR61","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nature11729","volume":"493","author":"MT Heneka","year":"2013","unstructured":"Heneka MT, et al. NLRP3 is activated in Alzheimer\u2019s disease and contributes to pathology in APP\/PS1 mice. Nature. 2013;493:674\u20138.","journal-title":"Nature"},{"key":"716_CR62","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nature25158","volume":"552","author":"C Venegas","year":"2017","unstructured":"Venegas C, et al. Microglia-derived ASC specks cross-seed amyloid-\u03b2 in Alzheimer\u2019s disease. Nature. 2017;552:355\u201361.","journal-title":"Nature"},{"key":"716_CR63","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s11481-021-10037-0","volume":"17","author":"Q Liu","year":"2022","unstructured":"Liu Q, et al. Inhibition of microglial NLRP3 with MCC950 attenuates microglial morphology and NLRP3\/caspase-1\/IL-1\u03b2 signaling in stress-induced mice. J Neuroimmune Pharmacol. 2022;17:503\u201314.","journal-title":"J Neuroimmune Pharmacol"},{"key":"716_CR64","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1089\/neu.2023.0444","volume":"41","author":"AR Ravula","year":"2024","unstructured":"Ravula AR, et al. MCC950 attenuates microglial NLRP3-mediated chronic neuroinflammation and memory impairment in a rat model of repeated low-level blast exposure. J Neurotrauma. 2024;41:1450\u201368.","journal-title":"J Neurotrauma"},{"key":"716_CR65","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.bbi.2016.12.014","volume":"61","author":"C Dempsey","year":"2017","unstructured":"Dempsey C, et al. Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-\u03b2 and cognitive function in APP\/PS1 mice. Brain Behav Immun. 2017;61:306\u201316.","journal-title":"Brain Behav Immun"},{"key":"716_CR66","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaf372","author":"EA Albornoz","year":"2025","unstructured":"Albornoz EA, et al. PET-MRI biomarkers reveal efficacy of a novel NLRP3 inhibitor in Parkinson\u2019s disease models. Brain. 2025. https:\/\/doi.org\/10.1093\/brain\/awaf372.","journal-title":"Brain"},{"key":"716_CR67","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41573-023-00822-2","volume":"23","author":"L Vande Walle","year":"2024","unstructured":"Vande Walle L, Lamkanfi M. Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets. Nat Rev Drug Discov. 2024;23:43\u201366.","journal-title":"Nat Rev Drug Discov"},{"key":"716_CR68","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/glia.20338","volume":"53","author":"TJ Seabrook","year":"2006","unstructured":"Seabrook TJ, Jiang L, Maier M, Lemere CA. Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice. Glia. 2006;53:776\u201382.","journal-title":"Glia"},{"key":"716_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118159","volume":"188","author":"G Forloni","year":"2025","unstructured":"Forloni G. Doxycycline: an essential tool for Alzheimer\u2019s disease. Biomed Pharmacother. 2025;188:118159.","journal-title":"Biomed Pharmacother"},{"key":"716_CR70","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jamaneurol.2019.3762","volume":"77","author":"R Howard","year":"2020","unstructured":"Howard R, et al. Minocycline at 2 different dosages vs placebo for patients with mild Alzheimer disease: a randomized clinical trial. JAMA Neurol. 2020;77:164\u201374.","journal-title":"JAMA Neurol"},{"key":"716_CR71","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1093\/brain\/awx339","volume":"141","author":"G Scott","year":"2018","unstructured":"Scott G, et al. Minocycline reduces chronic microglial activation after brain trauma but increases neurodegeneration. Brain. 2018;141:459\u201371.","journal-title":"Brain"},{"key":"716_CR72","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s43587-022-00337-2","volume":"3","author":"X Xie","year":"2023","unstructured":"Xie X, et al. Activation of innate immune cGAS-STING pathway contributes to Alzheimer\u2019s pathogenesis in 5\u00d7FAD mice. Nat Aging. 2023;3:202\u201312.","journal-title":"Nat Aging"},{"key":"716_CR73","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41586-023-06373-1","volume":"620","author":"MF Gulen","year":"2023","unstructured":"Gulen MF, et al. cGAS-STING drives ageing-related inflammation and neurodegeneration. Nature. 2023;620:374\u201380.","journal-title":"Nature"},{"key":"716_CR74","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41577-024-01112-7","volume":"25","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Zhang C. Regulation of cGAS-STING signalling and its diversity of cellular outcomes. Nat Rev Immunol. 2025;25:425\u201344.","journal-title":"Nat Rev Immunol"},{"key":"716_CR75","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/ana.23955","volume":"74","author":"P Podlesniy","year":"2013","unstructured":"Podlesniy P, et al. Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease. Ann Neurol. 2013;74:655\u201368.","journal-title":"Ann Neurol"},{"key":"716_CR76","doi-asserted-by":"publisher","first-page":"192.e191","DOI":"10.1016\/j.neurobiolaging.2016.12.009","volume":"53","author":"L Cervera-Carles","year":"2017","unstructured":"Cervera-Carles L, et al. Cerebrospinal fluid mitochondrial DNA in the Alzheimer\u2019s disease continuum. Neurobiol Aging. 2017;53:192.e191-192.e194.","journal-title":"Neurobiol Aging"},{"key":"716_CR77","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41593-023-01315-6","volume":"26","author":"JC Udeochu","year":"2023","unstructured":"Udeochu JC, et al. Tau activation of microglial cGAS-IFN reduces MEF2C-mediated cognitive resilience. Nat Neurosci. 2023;26:737\u201350.","journal-title":"Nat Neurosci"},{"key":"716_CR78","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2011226118","author":"Y Hou","year":"2021","unstructured":"Hou Y, et al. NAD(+) supplementation reduces neuroinflammation and cell senescence in a transgenic mouse model of Alzheimer\u2019s disease via cGAS-STING. Proc Natl Acad Sci U S A. 2021. https:\/\/doi.org\/10.1073\/pnas.2011226118.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"716_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-023-00343-3","volume":"12","author":"C de Dios","year":"2023","unstructured":"de Dios C, et al. Inflammasome activation under high cholesterol load triggers a protective microglial phenotype while promoting neuronal pyroptosis. Transl Neurodegener. 2023;12:10.","journal-title":"Transl Neurodegener"},{"key":"716_CR80","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13024-025-00893-2","volume":"20","author":"L La Barbera","year":"2025","unstructured":"La Barbera L, et al. Midbrain degeneration triggers astrocyte reactivity and tau pathology in experimental Alzheimer\u2019s disease. Mol Neurodegener. 2025;20:105.","journal-title":"Mol Neurodegener"},{"key":"716_CR81","doi-asserted-by":"crossref","unstructured":"Wen X, et al. Mitochondrial DNA in exercise-mediated innate immune responses. Int J Mol Sci. 26 (2025).","DOI":"10.3390\/ijms26073069"},{"key":"716_CR82","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/nn.4338","volume":"19","author":"RM Ransohoff","year":"2016","unstructured":"Ransohoff RM. A polarizing question: do M1 and M2 microglia exist? Nat Neurosci. 2016;19:987\u201391.","journal-title":"Nat Neurosci"},{"key":"716_CR83","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.celrep.2020.01.010","volume":"30","author":"T Masuda","year":"2020","unstructured":"Masuda T, Sankowski R, Staszewski O, Prinz M. Microglia heterogeneity in the single-cell era. Cell Rep. 2020;30:1271\u201381.","journal-title":"Cell Rep"},{"key":"716_CR84","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.cmet.2019.06.005","volume":"30","author":"SH Baik","year":"2019","unstructured":"Baik SH, et al. A breakdown in metabolic reprogramming causes microglia dysfunction in Alzheimer\u2019s disease. Cell Metab. 2019;30:493-507.e496.","journal-title":"Cell Metab"},{"key":"716_CR85","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12974-021-02187-y","volume":"18","author":"J Cheng","year":"2021","unstructured":"Cheng J, et al. Early glycolytic reprogramming controls microglial inflammatory activation. J Neuroinflammat. 2021;18:129.","journal-title":"J Neuroinflammat"},{"key":"716_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102846","volume":"66","author":"M Sangineto","year":"2023","unstructured":"Sangineto M, et al. Metabolic reprogramming in inflammatory microglia indicates a potential way of targeting inflammation in Alzheimer\u2019s disease. Redox Biol. 2023;66:102846.","journal-title":"Redox Biol"},{"key":"716_CR87","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41586-025-09098-5","volume":"644","author":"Z Wang","year":"2025","unstructured":"Wang Z, et al. Early life high fructose impairs microglial phagocytosis and neurodevelopment. Nature. 2025;644:759\u201368.","journal-title":"Nature"},{"key":"716_CR88","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/s43587-025-00869-3","volume":"5","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, et al. Activation of AMPK by GLP-1R agonists mitigates Alzheimer-related phenotypes in transgenic mice. Nat Aging. 2025;5:1097\u2013113.","journal-title":"Nat Aging"},{"key":"716_CR89","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1177\/13872877251351329","volume":"106","author":"W Wang","year":"2025","unstructured":"Wang W, et al. Associations of semaglutide with Alzheimer\u2019s disease-related dementias in patients with type 2 diabetes: a real-world target trial emulation study. J Alzheimers Dis. 2025;106:1509\u201322.","journal-title":"J Alzheimers Dis"},{"key":"716_CR90","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13195-024-01666-7","volume":"17","author":"JL Cummings","year":"2025","unstructured":"Cummings JL, et al. evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer\u2019s disease. Alzheimers Res Ther. 2025;17:14.","journal-title":"Alzheimers Res Ther"},{"key":"716_CR91","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1016\/j.immuni.2025.04.029","volume":"58","author":"P Prakash","year":"2025","unstructured":"Prakash P, et al. Amyloid-\u03b2 induces lipid droplet-mediated microglial dysfunction via the enzyme DGAT2 in Alzheimer\u2019s disease. Immunity. 2025;58:1536-1552.e1538.","journal-title":"Immunity"},{"key":"716_CR92","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41586-024-07185-7","volume":"628","author":"MS Haney","year":"2024","unstructured":"Haney MS, et al. APOE4\/4 is linked to damaging lipid droplets in Alzheimer\u2019s disease microglia. Nature. 2024;628:154\u201361.","journal-title":"Nature"},{"key":"716_CR93","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41593-019-0566-1","volume":"23","author":"J Marschallinger","year":"2020","unstructured":"Marschallinger J, et al. Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain. Nat Neurosci. 2020;23:194\u2013208.","journal-title":"Nat Neurosci"},{"key":"716_CR94","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/S1474-4422(25)00350-3","volume":"24","author":"CR Jack Jr.","year":"2025","unstructured":"Jack CR Jr., et al. Lifetime and 10-year absolute risk of cognitive impairment in relation to amyloid PET severity: a retrospective, longitudinal cohort study. Lancet Neurol. 2025;24:1016\u201325.","journal-title":"Lancet Neurol"},{"key":"716_CR95","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.8346443","volume":"261","author":"EH Corder","year":"1993","unstructured":"Corder EH, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families. Science. 1993;261:921\u20133.","journal-title":"Science"},{"key":"716_CR96","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.neuron.2018.05.008","volume":"98","author":"YT Lin","year":"2018","unstructured":"Lin YT, et al. APOE4 causes widespread molecular and cellular alterations associated with Alzheimer\u2019s disease phenotypes in human iPSC-derived brain cell types. Neuron. 2018;98:1141-1154.e1147.","journal-title":"Neuron"},{"key":"716_CR97","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1038\/s41591-025-03574-1","volume":"31","author":"L van Olst","year":"2025","unstructured":"van Olst L, et al. Microglial mechanisms drive amyloid-\u03b2 clearance in immunized patients with Alzheimer\u2019s disease. Nat Med. 2025;31:1604\u201316.","journal-title":"Nat Med"},{"key":"716_CR98","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.stem.2022.07.005","volume":"29","author":"MB Victor","year":"2022","unstructured":"Victor MB, et al. Lipid accumulation induced by APOE4 impairs microglial surveillance of neuronal-network activity. Cell Stem Cell. 2022;29:1197-1212.e1198.","journal-title":"Cell Stem Cell"},{"key":"716_CR99","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/s41590-023-01627-6","volume":"24","author":"Z Yin","year":"2023","unstructured":"Yin Z, et al. APOE4 impairs the microglial response in Alzheimer\u2019s disease by inducing TGF\u03b2-mediated checkpoints. Nat Immunol. 2023;24:1839\u201353.","journal-title":"Nat Immunol"},{"key":"716_CR100","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1038\/s41590-023-01640-9","volume":"24","author":"CC Liu","year":"2023","unstructured":"Liu CC, et al. Cell-autonomous effects of APOE4 in restricting microglial response in brain homeostasis and Alzheimer\u2019s disease. Nat Immunol. 2023;24:1854\u201366.","journal-title":"Nat Immunol"},{"key":"716_CR101","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.neuron.2025.02.017","volume":"113","author":"Z Li","year":"2025","unstructured":"Li Z, et al. APOE genotype determines cell-type-specific pathological landscape of Alzheimer\u2019s disease. Neuron. 2025;113:1380-1397.e1387.","journal-title":"Neuron"},{"key":"716_CR102","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.immuni.2023.12.001","volume":"57","author":"A Millet","year":"2024","unstructured":"Millet A, Ledo JH, Tavazoie SF. An exhausted-like microglial population accumulates in aged and APOE4 genotype Alzheimer\u2019s brains. Immunity. 2024;57:153-170.e156.","journal-title":"Immunity"},{"key":"716_CR103","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-025-03470-y","volume":"22","author":"M Hell\u00e9n","year":"2025","unstructured":"Hell\u00e9n M, et al. Inflammation-induced lysosomal dysfunction in human iPSC-derived microglia is exacerbated by APOE 4\/4 genotype. J Neuroinflammation. 2025;22:147.","journal-title":"J Neuroinflammation"},{"key":"716_CR104","doi-asserted-by":"crossref","unstructured":"Ferrari-Souza JP, et al. APOE\u03b54 associates with microglial activation independently of A\u03b2 plaques and tau tangles. Sci Adv 9, eade1474 (2023).","DOI":"10.1126\/sciadv.ade1474"},{"key":"716_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2025.106983","volume":"212","author":"CM Friday","year":"2025","unstructured":"Friday CM, et al. APOE4 reshapes the lipid droplet proteome and modulates microglial inflammatory responses. Neurobiol Dis. 2025;212:106983.","journal-title":"Neurobiol Dis"},{"key":"716_CR106","doi-asserted-by":"crossref","unstructured":"Golden LR, et al. APOE4 to APOE2 allelic switching in mice improves Alzheimer's disease-related metabolic signatures, neuropathology and cognition. Nat Neurosci, (2025).","DOI":"10.1038\/s41593-025-02094-y"},{"key":"716_CR107","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1089\/humc.2017.231","volume":"29","author":"JB Rosenberg","year":"2018","unstructured":"Rosenberg JB, et al. AAVrh.10-mediated APOE2 central nervous system gene therapy for APOE4-associated Alzheimer\u2019s disease. Hum Gene Ther Clin Dev. 2018;29:24\u201347.","journal-title":"Hum Gene Ther Clin Dev"},{"key":"716_CR108","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S1474-4422(21)00043-0","volume":"20","author":"DK Burns","year":"2021","unstructured":"Burns DK, et al. Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer\u2019s disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021;20:537\u201347.","journal-title":"Lancet Neurol"},{"key":"716_CR109","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaf462","author":"J Zu","year":"2025","unstructured":"Zu J, et al. Pioglitazone attenuates complement-mediated microglial synaptic engulfment in an Alzheimer\u2019s disease model. Brain. 2025. https:\/\/doi.org\/10.1093\/brain\/awaf462.","journal-title":"Brain"},{"issue":"Suppl 5","key":"716_CR110","doi-asserted-by":"publisher","DOI":"10.1002\/alz70859_104518","volume":"21","author":"U Raychaudhuri","year":"2025","unstructured":"Raychaudhuri U, et al. Drug development. Alzheimers Dement. 2025;21(Suppl 5):e104518.","journal-title":"Alzheimers Dement"},{"key":"716_CR111","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13195-022-01097-2","volume":"14","author":"J Vi\u00f1a","year":"2022","unstructured":"Vi\u00f1a J, et al. Genistein effect on cognition in prodromal Alzheimer\u2019s disease patients. The GENIAL clinical trial. Alzheimers Res Ther. 2022;14:164.","journal-title":"Alzheimers Res Ther"},{"key":"716_CR112","doi-asserted-by":"publisher","first-page":"6454","DOI":"10.1038\/s41467-023-42096-7","volume":"14","author":"AM Sabogal-Gu\u00e1queta","year":"2023","unstructured":"Sabogal-Gu\u00e1queta AM, et al. Species-specific metabolic reprogramming in human and mouse microglia during inflammatory pathway induction. Nat Commun. 2023;14:6454.","journal-title":"Nat Commun"},{"key":"716_CR113","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/glia.23913","volume":"69","author":"EM York","year":"2021","unstructured":"York EM, Zhang J, Choi HB, MacVicar BA. Neuroinflammatory inhibition of synaptic long-term potentiation requires immunometabolic reprogramming of microglia. Glia. 2021;69:567\u201378.","journal-title":"Glia"},{"key":"716_CR114","doi-asserted-by":"publisher","first-page":"14344","DOI":"10.1007\/s12035-025-04947-w","volume":"62","author":"A D\u017eidi\u0107-Krivi\u0107","year":"2025","unstructured":"D\u017eidi\u0107-Krivi\u0107 A, et al. Linking metabolic syndrome to neurodegeneration mechanisms and potential treatments. Mol Neurobiol. 2025;62:14344\u201366.","journal-title":"Mol Neurobiol"},{"key":"716_CR115","doi-asserted-by":"publisher","DOI":"10.3390\/ph18101527","author":"P Ormazabal","year":"2025","unstructured":"Ormazabal P, Bast\u00edas-P\u00e9rez M, Inestrosa NC, Cisternas P. Adipokines at the metabolic-brain interface: therapeutic modulation by antidiabetic agents and natural compounds in Alzheimer\u2019s disease. Pharmaceuticals (Basel). 2025. https:\/\/doi.org\/10.3390\/ph18101527.","journal-title":"Pharmaceuticals (Basel)"},{"key":"716_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.104956","volume":"142","author":"BT Casali","year":"2020","unstructured":"Casali BT, MacPherson KP, Reed-Geaghan EG, Landreth GE. Microglia depletion rapidly and reversibly alters amyloid pathology by modification of plaque compaction and morphologies. Neurobiol Dis. 2020;142:104956.","journal-title":"Neurobiol Dis"},{"key":"716_CR117","doi-asserted-by":"publisher","first-page":"30912","DOI":"10.1038\/s41598-024-81910-0","volume":"14","author":"LHD Le","year":"2024","unstructured":"Le LHD, O\u2019Banion MK, Majewska AK. Partial microglial depletion and repopulation exert subtle but differential effects on amyloid pathology at different disease stages. Sci Rep. 2024;14:30912.","journal-title":"Sci Rep"},{"key":"716_CR118","doi-asserted-by":"publisher","first-page":"11159","DOI":"10.1523\/JNEUROSCI.6209-10.2011","volume":"31","author":"A Mildner","year":"2011","unstructured":"Mildner A, et al. Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer\u2019s disease. J Neurosci. 2011;31:11159\u201371.","journal-title":"J Neurosci"},{"key":"716_CR119","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-017-0188-6","volume":"12","author":"R Zhao","year":"2017","unstructured":"Zhao R, Hu W, Tsai J, Li W, Gan WB. Microglia limit the expansion of \u03b2-amyloid plaques in a mouse model of Alzheimer\u2019s disease. Mol Neurodegener. 2017;12:47.","journal-title":"Mol Neurodegener"},{"key":"716_CR120","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11674-z","volume":"10","author":"E Spangenberg","year":"2019","unstructured":"Spangenberg E, et al. Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer\u2019s disease model. Nat Commun. 2019;10:3758.","journal-title":"Nat Commun"},{"key":"716_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112956","volume":"42","author":"P Mishra","year":"2023","unstructured":"Mishra P, et al. Rescue of Alzheimer\u2019s disease phenotype in a mouse model by transplantation of wild-type hematopoietic stem and progenitor cells. Cell Rep. 2023;42:112956.","journal-title":"Cell Rep"},{"key":"716_CR122","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1038\/s41593-019-0525-x","volume":"22","author":"R Mancuso","year":"2019","unstructured":"Mancuso R, et al. Stem-cell-derived human microglia transplanted in mouse brain to study human disease. Nat Neurosci. 2019;22:2111\u20136.","journal-title":"Nat Neurosci"},{"key":"716_CR123","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-018-0297-x","volume":"13","author":"A McQuade","year":"2018","unstructured":"McQuade A, et al. Development and validation of a simplified method to generate human microglia from pluripotent stem cells. Mol Neurodegener. 2018;13:67.","journal-title":"Mol Neurodegener"},{"key":"716_CR124","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.stem.2025.03.009","volume":"32","author":"JP Chadarevian","year":"2025","unstructured":"Chadarevian JP, et al. Harnessing human iPSC-microglia for CNS-wide delivery of disease-modifying proteins. Cell Stem Cell. 2025;32:914-934.e918.","journal-title":"Cell Stem Cell"},{"key":"716_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2021.100613","volume":"2","author":"Z Xu","year":"2021","unstructured":"Xu Z, Rao Y, Peng B. Protocol for microglia replacement by peripheral blood (Mr PB). STAR Protoc. 2021;2:100613.","journal-title":"STAR Protoc"},{"key":"716_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2021.100666","volume":"2","author":"Z Xu","year":"2021","unstructured":"Xu Z, Zhou X, Peng B, Rao Y. Microglia replacement by bone marrow transplantation (Mr BMT) in the central nervous system of adult mice. STAR Protoc. 2021;2:100666.","journal-title":"STAR Protoc"},{"key":"716_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2021.100665","volume":"2","author":"Z Xu","year":"2021","unstructured":"Xu Z, Peng B, Rao Y. Microglia replacement by microglia transplantation (Mr MT) in the adult mouse brain. STAR Protoc. 2021;2:100665.","journal-title":"STAR Protoc"},{"key":"716_CR128","doi-asserted-by":"publisher","DOI":"10.1126\/science.adr1015","volume":"389","author":"J Wu","year":"2025","unstructured":"Wu J, et al. Microglia replacement halts the progression of microgliopathy in mice and humans. Science. 2025;389:eadr1015.","journal-title":"Science"},{"key":"716_CR129","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-022-02393-2","volume":"19","author":"S Liu","year":"2022","unstructured":"Liu S, et al. Exosomes derived from bone-marrow mesenchymal stem cells alleviate cognitive decline in AD-like mice by improving BDNF-related neuropathology. J Neuroinflammation. 2022;19:35.","journal-title":"J Neuroinflammation"},{"key":"716_CR130","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.stem.2026.01.017","volume":"33","author":"JG Ruiz","year":"2026","unstructured":"Ruiz JG, et al. Randomized phase 2b dose-escalation trial of stem cell therapy with laromestrocel for aging frailty. Cell Stem Cell. 2026;33:393-404.e394.","journal-title":"Cell Stem Cell"},{"key":"716_CR131","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/s41591-025-03559-0","volume":"31","author":"BG Rash","year":"2025","unstructured":"Rash BG, et al. Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer\u2019s disease: a randomized controlled phase 2a trial. Nat Med. 2025;31:1257\u201366.","journal-title":"Nat Med"},{"key":"716_CR132","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1002\/sctm.19-0327","volume":"9","author":"M Losurdo","year":"2020","unstructured":"Losurdo M, et al. Intranasal delivery of mesenchymal stem cell-derived extracellular vesicles exerts immunomodulatory and neuroprotective effects in a 3xTg model of Alzheimer\u2019s disease. Stem Cells Transl Med. 2020;9:1068\u201384.","journal-title":"Stem Cells Transl Med"},{"key":"716_CR133","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.jconrel.2020.09.019","volume":"327","author":"X Ma","year":"2020","unstructured":"Ma X, et al. ADSCs-derived extracellular vesicles alleviate neuronal damage, promote neurogenesis and rescue memory loss in mice with Alzheimer\u2019s disease. J Control Release. 2020;327:688\u2013702.","journal-title":"J Control Release"},{"key":"716_CR134","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.jconrel.2024.11.060","volume":"377","author":"RO Silva","year":"2025","unstructured":"Silva RO, et al. Exploring the potential of plasma and adipose mesenchymal stem cell-derived extracellular vesicles as novel platforms for neuroinflammation therapy. J Control Release. 2025;377:880\u201398.","journal-title":"J Control Release"},{"key":"716_CR135","doi-asserted-by":"publisher","first-page":"8129","DOI":"10.7150\/thno.62069","volume":"11","author":"AS Cone","year":"2021","unstructured":"Cone AS, et al. Mesenchymal stem cell-derived extracellular vesicles ameliorate Alzheimer\u2019s disease-like phenotypes in a preclinical mouse model. Theranostics. 2021;11:8129\u201342.","journal-title":"Theranostics"},{"key":"716_CR136","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202207107","volume":"34","author":"F Xu","year":"2022","unstructured":"Xu F, et al. Engineered extracellular vesicles with SHP2 high expression promote mitophagy for Alzheimer\u2019s disease treatment. Adv Mater. 2022;34:e2207107.","journal-title":"Adv Mater"},{"key":"716_CR137","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12519","volume":"13","author":"LN Madhu","year":"2024","unstructured":"Madhu LN, et al. Extracellular vesicles from human-induced pluripotent stem cell-derived neural stem cells alleviate proinflammatory cascades within disease-associated microglia in Alzheimer\u2019s disease. J Extracell Vesicles. 2024;13:e12519.","journal-title":"J Extracell Vesicles"},{"key":"716_CR138","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/s43587-024-00612-4","volume":"4","author":"X Chen","year":"2024","unstructured":"Chen X, et al. Small extracellular vesicles from young plasma reverse age-related functional declines by improving mitochondrial energy metabolism. Nat Aging. 2024;4:814\u201338.","journal-title":"Nat Aging"},{"key":"716_CR139","doi-asserted-by":"crossref","unstructured":"Tan F, et al. Plant-derived extracellular vesicles as tools and targets for inflammatory diseases. J Nanobiotechnology 24, (2026).","DOI":"10.1186\/s12951-026-04294-5"},{"key":"716_CR140","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.1039\/D0FO02936J","volume":"12","author":"B Tian","year":"2021","unstructured":"Tian B, et al. Anthocyanins from the fruits of Lycium ruthenicum Murray improve high-fat diet-induced insulin resistance by ameliorating inflammation and oxidative stress in mice. Food Funct. 2021;12:3855\u201371.","journal-title":"Food Funct"},{"key":"716_CR141","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-025-03567-9","volume":"23","author":"Q Lv","year":"2025","unstructured":"Lv Q, et al. Prunus mume derived extracellular vesicle-like particles alleviate experimental colitis via disrupting NEK7-NLRP3 interaction and inflammasome activation. J Nanobiotechnol. 2025;23:532.","journal-title":"J Nanobiotechnol"},{"key":"716_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117235","volume":"178","author":"Y Shen","year":"2024","unstructured":"Shen Y, Liu F, Zhang M. Therapeutic potential of plant-derived natural compounds in Alzheimer\u2019s disease: targeting microglia-mediated neuroinflammation. Biomed Pharmacother. 2024;178:117235.","journal-title":"Biomed Pharmacother"},{"key":"716_CR143","doi-asserted-by":"publisher","first-page":"5407","DOI":"10.2147\/IJN.S514930","volume":"20","author":"X Luo","year":"2025","unstructured":"Luo X, et al. Mechanistic insights into the anti-glioma effects of exosome-like nanoparticles derived from Garcinia mangostana L.: a metabolomics, network pharmacology, and experimental study. Int J Nanomed. 2025;20:5407\u201327.","journal-title":"Int J Nanomed"},{"key":"716_CR144","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202505921","volume":"12","author":"R Shi","year":"2025","unstructured":"Shi R, et al. MicroRNA-enriched plant-derived exosomes alleviate colitis by modulating systemic immunity, metabolic homeostasis, and gut microbiota. Adv Sci. 2025;12:e05921.","journal-title":"Adv Sci"},{"key":"716_CR145","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-025-03466-z","volume":"23","author":"Y Yang","year":"2025","unstructured":"Yang Y, et al. Coptis chinensis-derived extracellular vesicle-like nanoparticles delivered miRNA-5106 suppresses NETs by restoring zinc homeostasis to alleviate colitis. J Nanobiotechnol. 2025;23:444.","journal-title":"J Nanobiotechnol"},{"key":"716_CR146","doi-asserted-by":"publisher","first-page":"47497","DOI":"10.1021\/acsami.5c09843","volume":"17","author":"S Sha","year":"2025","unstructured":"Sha S, et al. Engineered stem cell membrane-coated nanodrugs for targeted therapy of Alzheimer\u2019s disease. ACS Appl Mater Interfaces. 2025;17:47497\u2013511.","journal-title":"ACS Appl Mater Interfaces"},{"key":"716_CR147","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12255","volume":"11","author":"Z Zhu","year":"2022","unstructured":"Zhu Z, et al. Specific anti-glioma targeted-delivery strategy of engineered small extracellular vesicles dual-functionalised by Angiopep-2 and TAT peptides. J Extracell Vesicles. 2022;11:e12255.","journal-title":"J Extracell Vesicles"},{"key":"716_CR148","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60746-w","volume":"16","author":"Y Su","year":"2025","unstructured":"Su Y, et al. Connexin43 hemichannel blockade turns microglia neuroprotective and mitigates cognitive deficits in a mouse model of amyloidosis. Nat Commun. 2025;16:5621.","journal-title":"Nat Commun"},{"key":"716_CR149","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-025-03678-3","volume":"23","author":"J Chen","year":"2025","unstructured":"Chen J, et al. Targeted neural stem cell-derived extracellular vesicles loaded with Sinomenine alleviate diabetic peripheral neuropathy via WNT5a\/TRPV1 pathway modulation. J Nanobiotechnol. 2025;23:588.","journal-title":"J Nanobiotechnol"},{"key":"716_CR150","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.7150\/thno.106083","volume":"15","author":"A Casamassa","year":"2025","unstructured":"Casamassa A, et al. A new nano-encapsulated TSPO ligand reduces neuroinflammation and improves cognitive functions in Alzheimer\u2019s disease model. Theranostics. 2025;15:4673\u201392.","journal-title":"Theranostics"},{"key":"716_CR151","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ijpharm.2013.02.014","volume":"446","author":"PA Patel","year":"2013","unstructured":"Patel PA, Patil SC, Kalaria DR, Kalia YN, Patravale VB. Comparative in vitro and in vivo evaluation of lipid based nanocarriers of Huperzine A. Int J Pharm. 2013;446:16\u201323.","journal-title":"Int J Pharm"},{"key":"716_CR152","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.3109\/10717544.2015.1089956","volume":"23","author":"S Misra","year":"2016","unstructured":"Misra S, Chopra K, Sinha VR, Medhi B. Galantamine-loaded solid-lipid nanoparticles for enhanced brain delivery: preparation, characterization, in vitro and in vivo evaluations. Drug Deliv. 2016;23:1434\u201343.","journal-title":"Drug Deliv"},{"key":"716_CR153","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-019-2691-7","volume":"36","author":"B Dos Santos Rodrigues","year":"2019","unstructured":"Dos Santos Rodrigues B, Kanekiyo T, Singh J. ApoE-2 brain-targeted gene therapy through transferrin and penetratin tagged liposomal nanoparticles. Pharm Res. 2019;36:161.","journal-title":"Pharm Res"},{"key":"716_CR154","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114397","volume":"187","author":"P Delbreil","year":"2022","unstructured":"Delbreil P, Rabanel JM, Banquy X, Brambilla D. Therapeutic nanotechnologies for Alzheimer\u2019s disease: a critical analysis of recent trends and findings. Adv Drug Deliv Rev. 2022;187:114397.","journal-title":"Adv Drug Deliv Rev"},{"key":"716_CR155","doi-asserted-by":"publisher","DOI":"10.1136\/gpsych-2023-101143","volume":"36","author":"X Xie","year":"2023","unstructured":"Xie X, et al. Clinical safety and efficacy of allogenic human adipose mesenchymal stromal cells-derived exosomes in patients with mild to moderate Alzheimer\u2019s disease: a phase I\/II clinical trial. Gen Psychiatr. 2023;36:e101143.","journal-title":"Gen Psychiatr"},{"key":"716_CR156","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.70209","volume":"14","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, et al. Unveiling heterogeneity: innovations and challenges in single-vesicle analysis for clinical translation. J Extracell Vesicles. 2025;14:e70209.","journal-title":"J Extracell Vesicles"},{"key":"716_CR157","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41582-025-01080-z","volume":"21","author":"A Manolopoulos","year":"2025","unstructured":"Manolopoulos A, Yao PJ, Kapogiannis D. Extracellular vesicles: translational research and applications in neurology. Nat Rev Neurol. 2025;21:265\u201382.","journal-title":"Nat Rev Neurol"},{"key":"716_CR158","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/s43587-025-00879-1","volume":"5","author":"AR Gomez","year":"2025","unstructured":"Gomez AR, et al. Boosting angiotensin-converting enzyme (ACE) in microglia protects against Alzheimer\u2019s disease in 5xFAD mice. Nat Aging. 2025;5:1280\u201394.","journal-title":"Nat Aging"},{"key":"716_CR159","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1016\/j.immuni.2025.04.018","volume":"58","author":"J Liu","year":"2025","unstructured":"Liu J, et al. Microglial TMEM119 binds to amyloid-\u03b2 to promote its clearance in an A\u03b2-depositing mouse model of Alzheimer\u2019s disease. Immunity. 2025;58:1830-1846.e1837.","journal-title":"Immunity"},{"key":"716_CR160","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1016\/j.neuron.2025.06.020","volume":"113","author":"B Zhu","year":"2025","unstructured":"Zhu B, et al. G-protein-coupled receptor ADGRG1 drives a protective microglial state in Alzheimer\u2019s disease through MYC activation. Neuron. 2025;113:3224-3242.e3227.","journal-title":"Neuron"},{"key":"716_CR161","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41586-025-08852-z","volume":"641","author":"K Kimura","year":"2025","unstructured":"Kimura K, et al. Immune checkpoint TIM-3 regulates microglia and Alzheimer\u2019s disease. Nature. 2025;641:718\u201331.","journal-title":"Nature"},{"key":"716_CR162","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41590-021-00913-5","volume":"22","author":"Y Huang","year":"2021","unstructured":"Huang Y, et al. Microglia use TAM receptors to detect and engulf amyloid \u03b2 plaques. Nat Immunol. 2021;22:586\u201394.","journal-title":"Nat Immunol"},{"key":"716_CR163","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adw7428","volume":"17","author":"TN Weerakkody","year":"2025","unstructured":"Weerakkody TN, et al. Loss of PILRA promotes microglial immunometabolism to reduce amyloid pathology in cell and mouse models of Alzheimer\u2019s disease. Sci Transl Med. 2025;17:eadw7428.","journal-title":"Sci Transl Med"},{"key":"716_CR164","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1038\/s43587-025-00976-1","volume":"5","author":"M Gao","year":"2025","unstructured":"Gao M, et al. Loss of MFE-2 impairs microglial lipid homeostasis and drives neuroinflammation in Alzheimer\u2019s pathogenesis. Nat Aging. 2025;5:2279\u201396.","journal-title":"Nat Aging"},{"key":"716_CR165","doi-asserted-by":"publisher","first-page":"7552","DOI":"10.1038\/s41467-023-42819-w","volume":"14","author":"V Chou","year":"2023","unstructured":"Chou V, et al. INPP5D regulates inflammasome activation in human microglia. Nat Commun. 2023;14:7552.","journal-title":"Nat Commun"},{"key":"716_CR166","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.neuron.2022.10.021","volume":"111","author":"J Hu","year":"2023","unstructured":"Hu J, et al. Microglial Piezo1 senses A\u03b2 fibril stiffness to restrict Alzheimer\u2019s disease. Neuron. 2023;111:15-29.e18.","journal-title":"Neuron"},{"key":"716_CR167","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/s42255-022-00643-4","volume":"4","author":"L Leng","year":"2022","unstructured":"Leng L, et al. Microglial hexokinase 2 deficiency increases ATP generation through lipid metabolism leading to \u03b2-amyloid clearance. Nat Metab. 2022;4:1287\u2013305.","journal-title":"Nat Metab"},{"key":"716_CR168","doi-asserted-by":"publisher","first-page":"7028","DOI":"10.1038\/s41467-024-51163-6","volume":"15","author":"ND Schartz","year":"2024","unstructured":"Schartz ND, et al. C5aR1 antagonism suppresses inflammatory glial responses and alters cellular signaling in an Alzheimer\u2019s disease mouse model. Nat Commun. 2024;15:7028.","journal-title":"Nat Commun"},{"key":"716_CR169","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2025.10.022","author":"J Zhou","year":"2025","unstructured":"Zhou J, et al. C5aR1(+) microglia exacerbate neuroinflammation and cerebral edema in acute brain injury. Neuron. 2025. https:\/\/doi.org\/10.1016\/j.neuron.2025.10.022.","journal-title":"Neuron"},{"key":"716_CR170","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s43587-023-00491-1","volume":"3","author":"SF Lau","year":"2023","unstructured":"Lau SF, et al. The VCAM1-ApoE pathway directs microglial chemotaxis and alleviates Alzheimer\u2019s disease pathology. Nat Aging. 2023;3:1219\u201336.","journal-title":"Nat Aging"},{"key":"716_CR171","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.neuron.2023.12.003","volume":"112","author":"Z Lv","year":"2024","unstructured":"Lv Z, et al. Clearance of \u03b2-amyloid and synapses by the optogenetic depolarization of microglia is complement selective. Neuron. 2024;112:740-754.e747.","journal-title":"Neuron"},{"key":"716_CR172","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/s43587-022-00281-1","volume":"2","author":"B Dejanovic","year":"2022","unstructured":"Dejanovic B, et al. Complement C1q-dependent excitatory and inhibitory synapse elimination by astrocytes and microglia in Alzheimer\u2019s disease mouse models. Nat Aging. 2022;2:837\u201350.","journal-title":"Nat Aging"},{"key":"716_CR173","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1016\/j.cell.2022.09.030","volume":"185","author":"H Ennerfelt","year":"2022","unstructured":"Ennerfelt H, et al. SYK coordinates neuroprotective microglial responses in neurodegenerative disease. Cell. 2022;185:4135-4152.e4122.","journal-title":"Cell"}],"container-title":["Biological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40659-026-00716-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40659-026-00716-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40659-026-00716-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:03:20Z","timestamp":1791216200000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40659-026-00716-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":173,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["716"],"URL":"https:\/\/doi.org\/10.1186\/s40659-026-00716-8","relation":{},"ISSN":["0717-6287"],"issn-type":[{"value":"0717-6287","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"19 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"56"}}